This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell
autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell
acute lymphoblastic leukemia.
This is a multiple-center, single-arm, open-label study. After meeting the eligibility
criteria and enrolling on the trial, patients will undergo leukapheresis for collection of
autologous lymphocytes. Once cells have been manufactured, patients will then proceed to
lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3
consecutive days followed by the infusion of CD19 CAR T-cells at a target dose of 0.6-2 x106
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.